Aquestive Therapeutics shared its Q3 2026 results, showing lower total revenue and updates on its Anaphylm application.

Nov 4, 2026, 9:24 AM ETResultsRead the original at Benzinga

Neutral

Aquestive's sales fell, but it also received a $10 million Libervant payment, cut spending, and resubmitted Anaphylm. Since FDA approval is still pending and the 2026 forecast is unchanged, these facts do not clearly shift its outlook.

AQST · Aquestive Therapeutics

AI read · Neutral

The AI's read

The sales drop and expected loss show the company is still spending ahead of a possible product launch. Its $90.3 million cash balance, lower spending, and Libervant payment provide support. But Anaphylm still needs FDA approval, and access to another $95 million depends on that approval.

Get alerts for AQST

Follow Aquestive Therapeutics (AQST) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AQST

Free on the App Store and Google Play, or on the web.